Method of treating hyperproliferative diseases using active vitamin D analogues

• US 20030130242A1
• Filed: 01/07/2003
• Published: 07/10/2003
• Est. Priority Date: 12/30/1996
• Status: Active Grant

• Current Assignee: Bone Care International LLC
• Original Assignee: Bone Care International LLC
• Inventors: Bishop, Charles W., Mazess, Richard B.
• Granted Patent: US 6,680,309 B2
• Time in Patent Office: Days
• US Class Current: 514/167
• CPC Class Codes: A61K 31/59 Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/02 specific for leukemia
• CPC Class Codes: A61P 35/04 specific for metastasis
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Methods for the utilization of hypocalcemic vitamin D analogs to inhibit the hyperproliferation of malignant or neoplastic cells without incidence of hypercalcemia.

Claims

1. A method of inhibiting hyperproliferation of malignant or neoplastic cells, comprising treating the cells with an antiproliferative amount of a hypocalcemic hydroxyvitamin D compound having a hydrocarbon moiety at the C₂₄ position, the cells expressing a vitamin D receptor.

2. The method of claim 1, wherein the cells are cancers of the breast, colon, lung, neck and head, pancreas, endometrium, bladder, cervix, testes, ovaries, squamous cell carcinoma, myeloid and lymphocytic leukemia, lymphoma, medullary thyroid carcinoma, melanoma, multiple myeloma, retinoblastoma or sarcomas of the soft tissues and bone.

3. The method of claim 1, wherein the hypocalcemic vitamin D is a compound represented by formula (I)

4. A method in accordance with claim 1 wherein the hypocalcemic vitamin D compound is a compound of formula II

5. A method in accordance with claim 1, wherein the hypocalcemic vitamin D compound is a compound of formula III:

24. The method of claim 5, wherein the compound of formula (III) is 1α

,24-dihydroxyvitamin D₂, 1α

,24-dihydroxyvitamin D₄, 1α

,25-dihydroxyvitamin D₂, 1α

,25-dihydroxyvitamin D₄, 1α

-hydroxyvitamin D₂ or 1α

-hydroxyvitamin D₄.

6. A method of inhibiting the hyperproliferative activity of malignant or neoplastic cells, comprising administering to a patient suffering therefrom, an anitproliferarive amount of a hypocalcemic hydroxyvitamin D compound.

7. A method in accordance with claim 6, wherein the hypocalcemic vitamin D compound is administered in a daily regimen or an episodic regimen.

8. A method in accordance with claim 7, wherein the espisodic regimen is a dose once every 2 to 7 days.

9. A method in accordance with claim 7, wherein the hypocalcemic vitamin D compound is administered daily at a dose of about 10 to 100 μ

g/day.

10. A method in accordance with claim 6, wherein the hypocalcemic vitamin D compound is administered orally, is administered intravenously, is directly injected to a cancer site or is regionally delivered to a cancer site.

11. A method in accordance with claim 10, wherein the hypocalcemic vitamin D compound is administered orally.

12. A method in accordance with claim 6, wherein the hypocalcemic vitamin D compound is co-administered with a cytotoxic agent.

13. A method in accordance with claim 12, wherein the cytotoxic agent is an antimetabolite, and antimicrotubule agent, an alkyating agent, a platinum agent, an anthracycline, a topoisomase inhibitor, or an antibiotic.

14. A method in accordance with claim 13, wherein the antimetabolite is 5-fluoro-uracil, methotrexate or fludarabine.

15. A method in accordance with claim 13, wherein the antimicrotubule agent is vincristine, vinblastine or a taxane.

16. A method in accordance with claim 14, wherein the taxane is paclitaxel or docetaxel.

17. A method in accordance with claim 12, wherein the alkylating agent is cyclophasphamide, melphalan, biochoroethylnitrosurea or hydroxyurea.

18. A method in accordance with claim 12, wherein the platinum agent is cisplatin, carboplatin, oxaliplatin, JM-216 or CI-973.

19. A method in accordance with claim 12, wherein the anthracycline is doxrubicin or daunorubicin.

20. A method in accordance with claim 12, wherein the antibiotic is mitomycin, idarubicin, adriamycin or daunomycin.

21. A method in accordance with claim 12, wherein the topoisomerase inhibitior is etoposide or camptothecins.

22. A method in accordance with claim 12, wherein the cytotoxic agent is estramustine phosphate or prednimustine.

23. A method in accordance with claim 11, wherein an antiproliferative effective amount of the cytotoxic agent is lower than the antiproliferative effective amount of the cytotoxic agent when administered alone.

25. A method of treating a human to alleviate the pathological effects of breast cancer, colon cancer, testicular cancer, pancreatic cancer, endometrial cancer, small cell and non-small cell cancer of the lung (including squamous, adneocarcinoma and large cell types), squamous cell of the head and neck, bladder, ovarian and cervical cancers, myeloid and lymphocyltic leukemia, lymphoma, hepatic tumors, medullary thyroid carcinoma, multiple myeloma, melanoma, retinoblastoma or sarcomas of the soft tissue and bone, comprising administering to the human an therapeutic amount of a hypocalcemic hydroxyvitamin D compound.

26. A method of claim 25, wherein said hypocalcemic vitamin D is a 1α

-hydroxyvitamin D compound represented by formula (III)

27. The method of claim 26, wherein said therapeutic amount is 0.01 μ

g/kg/day to 2.0 μ

g/kg/day.

28. The method of claim 26, wherein the compound of formula (III) is 1α

,24-dihydroxyvitamin D₂, 1α

,24-dihydroxyvitamin D₄, 1α

,25-dihydroxyvitamin D₂, 1α

,25-dihydroxyvitamin D₄, 1α

-hydroxyvitamin D₂ or 1α

-hydroxyvitamin D₄.

29. A method of enhancing the antiproliferative effect of a cytotoxic agent in a patient with a disease in need of treatment by a cytotoxic agent, comprising administering to the patient a therapeutic amount of hypocalcemic vitamin D compound and the cytotoxic agent.

30. A method in accordance with claim 29, wherein the hypocalcemic vitamin D compound is administered from 0.5 to 7 days prior to administration of the cytotoxic agent.

31. A method in accordance with claim 29, wherein the hypocalcemic vitamin D compound is administered 2 to 4 days prior to administration of the cytotoxic agent.

32. A method of claim 29, wherein said hypocalcemic vitamin D is a 1α

-hydroxyvitamin D compound represented by formula (III)

33. The method of claim 32, wherein said therapeutic amount of the vitamin D compound is 0.01 μ

g/kg/day to 2.0 μ

g/kg/day.

34. The method of claim 32, wherein the compound of formula (III) is 1α

,24-dihydroxyvitamin D₂, 1α

,24-dihydroxyvitamin D₄, 1α

,25-dihydroxyvitamin D₂, 1α

,25-dihydroxyvitamin D₄, 1α

-hydroxyvitamin D₂ or 1α

-hydroxyvitamin D₄.

35. A method in accordance with claim 32, wherein the cytotoxic agent is an antimetabolite, and antimicrotubule agent, an alkyating agent, a platinum agent, an anthracycline, a topoisomase inhibitor, or an antibiotic.

36. A method of inducing differentiation in malignant or neoplastic cells, comprising treating to the cells with a prodifferentiative amount of a hypocalcemic vitamin D compound.

37. A method of treating in a subject tumor or neoplasm that expresses a vitamin D receptor, comprising administering to the subject an effective amount of hypocalcemic vitamin D compound sufficient to raise a blood level of vitamin D to a sufficiently supraphysiological level for a sufficient period of time to inhibit growth of the tumor or neoplasm without causing hypercalcemia in the subject.